Skip to main content
. Author manuscript; available in PMC: 2020 Feb 15.
Published in final edited form as: Oncogene. 2019 Aug 15;38(48):7329–7341. doi: 10.1038/s41388-019-0945-9

Figure 6.

Figure 6.

MK2 pathway blockade enhances RT sensitivity and blocks RT-induced pro-tumorigenic cytokine production, in vivo. A and C, Fold change in HN009LN (p16+) and HN011T (p16−) tumor volumes in mice treated with excipient, RT, MK2i, or RT+MK2i. B and D, PDX tumor survival curves. Athymic nude mice xenografted with HN009LN (A) and HN011T (C) tumors were monitored and euthanized appropriately per IACUC approved protocol when their tumors reached 2000 mm3, tumors became ulcerated or animals became moribund. Kaplan-Meier survival curves were generated comparing excipient/control, MK2i, RT or RT+MK2i treatment arms. Survival was measured from the first day of treatment onwards. P values noted in the survival curve (n = 5-6 animals per arm). Significance: * = p<0.05; ** = p<0.01; *** = p<0.001.